{"entity":{"id":"jonathan-spicer","kind":"person","name":"Jonathan Spicer","aka":[],"tldr":"The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder.","summary":"Jonathan Spicer led the surgical analyses of CheckMate 816, demonstrating that neoadjuvant nivolumab plus chemotherapy did not delay or complicate surgery and increased the rate of complete resection, which removed a key objection to neoadjuvant immunotherapy. He co-authored the five-year update and leads perioperative surgical research at McGill.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spicer%20JD%5BAuthor%5D%20neoadjuvant%20lung%20surgery"}],"tags":["lung","surgery","neoadjuvant"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":["mcgill-goodman"],"pathways":[],"terms":[],"trials":["checkmate-816"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-816-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic Surgeon and Associate Professor of Surgery, McGill University Health Centre","institutionId":"mcgill-goodman","specialisms":["Thoracic surgery","Neoadjuvant immunotherapy","Surgical outcomes in trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spicer%20JD%5BAuthor%5D%20neoadjuvant%20lung%20surgery"}],"papers":[{"title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer (CheckMate 816)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2202170"},{"title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab plus platinum-doublet chemotherapy vs chemotherapy alone as neoadjuvant treatment for resectable non-small cell lung cancer","journal":"JAMA Oncology","year":2023}],"orcid":"0000-0003-2708-1309"},"route":"/people/jonathan-spicer/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/"}],"trial":[{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/"}],"paper":[{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/"}]}}